Compare STEX & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | SEER |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 97.3M |
| IPO Year | N/A | 2020 |
| Metric | STEX | SEER |
|---|---|---|
| Price | $1.06 | $1.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 214.1K |
| Earning Date | 05-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,578,000.00 |
| Revenue This Year | N/A | $2.14 |
| Revenue Next Year | $1,044.81 | $25.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.99 |
| 52 Week Low | $0.70 | $1.65 |
| 52 Week High | $7.44 | $2.41 |
| Indicator | STEX | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 44.81 |
| Support Level | $0.98 | $1.76 |
| Resistance Level | $1.21 | $1.84 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.36 | 48.08 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.